Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. reports news about its continuous glucose monitoring and glucose biosensing business for people with diabetes. Company updates commonly cover Dexcom G7 clinical evidence, product roadmap activity, U.S. and international revenue trends, margins, guidance, and presentations at diabetes technology and healthcare investor conferences.
Dexcom news also includes corporate governance developments, board appointments, management presentations, and long-term strategy discussions tied to its CGM portfolio, global commercialization, and innovation in metabolic health.
DexCom, Inc. (NASDAQ: DXCM) has appointed Kyle Malady to its Board of Directors, effective immediately. Malady currently serves as executive vice president and chief technology officer at Verizon, overseeing global network operations and IT functions. With over 30 years of experience in mobile communications technology, Malady's extensive background is expected to enhance DexCom's leadership in continuous glucose monitoring and data analytics. His appointment aims to bolster DexCom’s efforts to empower diabetes management.
DexCom, Inc. (NASDAQ:DXCM) is set to release its third quarter 2020 financial results on October 27, 2020, after market close. A conference call will follow at 4:30 p.m. Eastern Time, where management will discuss the company's performance. Interested parties can access the call by dialing (800) 447-0521 (US/Canada) or (847) 413-3238 (International) with confirmation number '49260065'. DexCom is a leader in continuous glucose monitoring systems, dedicated to improving diabetes management for users, caregivers, and healthcare providers.